tive responses in melanoma90 and remains an area
of active further investigation.
In the United States, the incidence of melanoma
is rising faster than any other malignancy without
any corresponding decrease in mortality. Although
many melanomas are diagnosed at early stages
and can be cured with surgical excision, melanoma remains a vexing clinical problem, particularly
in the setting of metastatic disease. With the recent
advances in the molecular biology of this disease,
it is hoped these new discoveries will be exploited
for novel prevention and therapeutic strategies in
the years to come.
Test your knowledge of this topic.
Go to www.turner-white.com and select Oncology
from the drop-down menu of specialties.
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
CA Cancer J Clin 2012;62:10–29.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA
Cancer J Clin 2007;57:43–66.
3. Edwards BK, Brown ML, Wingo PA, et al. Annual report to
the nation on the status of cancer, 1975-2002, featuring
population-based trends in cancer treatment. J Natl Cancer
4. Lamberg L. “Epidemic” of malignant melanoma: true increase or better detection? JAMA 2002;287:2201.
5. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006;
6. Veierød MB, Weiderpass E, Thörn M, et al. A prospective
study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst
7. Flaherty KT, Robert C, Hersey P, et al; METRIC Study
Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107–14.
8. Bulliard JL, Cox B, Elwood JM. Latitude gradients in mela-
noma incidence and mortality in the non-Maori population of
New Zealand. Cancer Causes Control 1994;5:234–40.
9. Eide MJ, Weinstock MA. Association of UV index, latitude,
and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program,
1992 to 2001. Arch Dermatol 2005;141:477–81.
10. Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps,
and risk of cutaneous malignant melanoma. Cancer Epide-miol Biomarkers Prev 2005;14:562–6.
11. Westerdahl J, Ingvar C, Masback A, et al. Risk of cutaneous malignant melanoma in relation to use of sunbeds:
further evidence for UV-A carcinogenicity. Br J Cancer
12. Fisher DE, James WD. Indoor tanning--science, behavior,
and policy. N Engl J Med 2010;363:901–3.
13. Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the
red hair/fair skin background. Nature 2012;491:449–53.
14. Cormier JN, Xing Y, Ding M, et al. Ethnic differences
among patients with cutaneous melanoma. Arch Intern Med
15. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of
risk factors for cutaneous melanoma: II. Sun exposure. Eur
J Cancer 2005;41:45–60.
16. Bliss JM, Ford D, Swerdlow AJ, et al. Risk of cutaneous
melanoma associated with pigmentation characteristics and
freckling: systematic overview of 10 case-control studies.
The International Melanoma Analysis Group (IMAGE). Int J
17. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with
red hair and fair skin in humans. Nat Genet 1995;11:328–30.
18. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies
risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69:765–73.
19. Landi MT, Bauer J, Pfeiffer RM, et al. MC1R germline
variants confer risk for BRAF-mutant melanoma. Science
20. Cameron FR. Melanoma of skin. Clinical account of a series
of 209 malignant melanomas of skin. J R Coll Surg Edinb
21. Friedman RJ, Rigel DS, Kopf AW, et al. Favorable prognosis
for malignant melanomas associated with acquired melano-cytic nevi. Arch Dermatol 1983;119:455–62.
22. Jones WM, Williams WJ, Roberts MM, Davies K. Malignant
melanoma of the skin: prognostic value of clinical features and the role of treatment in 111 cases. Br J Cancer
23. Negin BP, Riedel E, Oliveria SA, et al. Symptoms and signs
of primary melanoma: important indicators of Breslow
depth. Cancer 2003;98:344–8.